EUVIMEDEUVIMED entdecken
Multizentrische Studie

Safety and Efficacy of Esomeprazole-Containing Regimens for Helicobacter pylori Eradication: A Multicenter Retrospective Study

Mohamed Alboraie, Hatem Elalfy, Mohamed M Mabrouk, Sameh A Lashen, Marwan Elgohary, Ossama Ashraf Ahmed, Mohamed Abdelmalek, Tamer Haydara, Mina Tharwat, Mohammad Aamr, Sherief Abdel-Salam, Omar Ashoush und 8 weitere

Digestive Diseases · 11.03.2026 · 44 (3) · 260-269

DOI: 10.1159/000551339 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive Diseases, online erschienen am 11.03.2026. Verfasst von Mohamed Alboraie und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Al-Azhar University, Cairo, Egypt, alboraie@azhar.edu.eg. Hauptthemen laut MEDLINE: Esomeprazole, Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Helicobacter pylori is a major global health challenge, causing significant gastrointestinal diseases and contributing to gastric cancer risk. This study evaluated the safety and efficacy of esomeprazole-containing regimens for H. pylori eradication in treatment-naïve and previously treated patients.

Methods

This retrospective multicenter cohort study included 2,530 patients diagnosed with H. pylori infection. Patients received one of five esomeprazole-containing regimens for 14 days. Eradication was assessed 4–6 weeks post-treatment using stool antigen tests, urea breath tests, or histopathology. Analyses included intention to treat (ITT) and per protocol (PP). Demographics, socioeconomic status, prior treatment history, adverse events, and eradication rates were analyzed.

Results

Of 2,530 enrolled, 2,489 were analyzed per protocol. The overall eradication rate was 87.3% (ITT) and 88.7% (PP). Treatment-naïve patients achieved higher eradication rates (89.7%) compared with previously treated patients (85.2%, p = 0.003). Bismuth subcitrate-based (96.5% PP in naïve; 86.7% in experienced) and doxycycline-based regimens (92.3% PP in naïve; 84.3% in experienced) demonstrated the highest efficacy. Adverse events occurred in 34.9% of patients, with no severe events. Socioeconomic status influenced outcomes, with eradication rates of 90.8% in high, 89.4% in middle, and 80.0% in low SES groups (p = 0.0001).

Conclusions

Esomeprazole-containing regimens are effective and well tolerated for H. pylori eradication. Bismuth- and doxycycline-based quadruple therapies achieved the highest eradication rates, particularly in treatment-naïve patients. Tailored strategies incorporating bismuth or quadruple therapy may benefit patients with prior treatment failures or from lower socioeconomic backgrounds. Further research should consider regional resistance patterns and prospective designs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EsomeprazoleHelicobacter InfectionsHelicobacter pyloriAnti-Bacterial AgentsProton Pump InhibitorsHumansRetrospective StudiesFemaleMaleMiddle AgedTreatment OutcomeDrug Therapy, CombinationAged

Stichwörter der Autor:innen

EsomeprazoleHelicobacter pyloriProton pump inhibitorQuadruple therapy

Substanzen

EsomeprazoleAnti-Bacterial AgentsProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Al-Azhar University, Cairo, Egypt, alboraie@azhar.edu.eg.
  • Department of Endemic Medicine, Mansoura University, Mansoura, Egypt.
  • Internal Medicine Department, Tanta University Hospital, Tanta, Egypt.
  • Department of Internal Medicine (Hepatology and Gastroenterology Division), Faculty of Medicine, Alexandria University, Alexandria, Egypt.
  • Internal Medicine Department, Zagazig University, Zagazig, Egypt.
  • Internal Medicine Department, Hepatology and Gastroenterology Ain Shams University, Cairo, Egypt.

Zitieren

APA

Alboraie, M., Elalfy, H., Mabrouk, M. M., Lashen, S. A., Elgohary, M., Ahmed, O. A., Abdelmalek, M., Haydara, T., Tharwat, M., Aamr, M., Abdel-Salam, S., Ashoush, O., Abdeen, N., Abdelghani, M., Elkhadry, S. W., Malak, M., Abdelaziz, A., Hassan, E. A., Bahaa, A., & Tag-Adeen, M. (2026). Safety and Efficacy of Esomeprazole-Containing Regimens for Helicobacter pylori Eradication: A Multicenter Retrospective Study. Digestive Diseases, 44(3), 260-269. https://doi.org/10.1159/000551339

Vancouver

Alboraie M, Elalfy H, Mabrouk MM, Lashen SA, Elgohary M, Ahmed OA, et al. Safety and Efficacy of Esomeprazole-Containing Regimens for Helicobacter pylori Eradication: A Multicenter Retrospective Study. Digestive Diseases. 2026;44(3):260-269. doi:10.1159/000551339

BibTeX
@article{Alboraie2026,
  author = {Alboraie, Mohamed and Elalfy, Hatem and Mabrouk, Mohamed M and Lashen, Sameh A and Elgohary, Marwan and Ahmed, Ossama Ashraf and Abdelmalek, Mohamed and Haydara, Tamer and Tharwat, Mina and Aamr, Mohammad and Abdel-Salam, Sherief and Ashoush, Omar and Abdeen, Nermeen and Abdelghani, Mohamed and Elkhadry, Sally Waheed and Malak, Mohamed and Abdelaziz, Ahmed and Hassan, Essam Aly and Bahaa, Ahmed and Tag-Adeen, Mohammed},
  title = {Safety and Efficacy of Esomeprazole-Containing Regimens for Helicobacter pylori Eradication: A Multicenter Retrospective Study},
  journal = {Digestive Diseases},
  year = {2026},
  volume = {44},
  number = {3},
  pages = {260--269},
  doi = {10.1159/000551339}
}
Kostenlos starten →